Uterine Fibroid Market Trends, Key Strategies, Size, Growth, Share, Application, Segmentation, Trends and Opportunities Forecast to 2032
The uterine fibroid market size is projected to grow at a compound annual growth rate (CAGR) of 2.80% during the forecast period.
Uterine fibroids, a prevalent health concern among women,
have spurred significant advancements in the healthcare industry, giving rise
to a dynamic Uterine Fibroid Market. Characterized by non-cancerous growths in
the uterus, these fibroids, also known as leiomyomas or myomas, affect a
substantial percentage of women during their reproductive years.
Fibroid
Disease Landscape: The market landscape for uterine
fibroids has witnessed a paradigm shift in recent years, fueled by an
increasing awareness of the condition and advancements in medical technologies.
These growths, varying in size and location within the uterus, can lead to a
range of symptoms such as heavy menstrual bleeding, pelvic pain, and
reproductive challenges.
Diagnostic Innovations: Diagnostic technologies
play a pivotal role in the uterine fibroid market, enabling early detection and
personalized treatment strategies. Magnetic Resonance Imaging (MRI),
ultrasound, and hysteroscopy have emerged as crucial tools for accurate
diagnosis, guiding healthcare professionals in tailoring effective
interventions.
Treatment Modalities: The market reflects a
diverse array of treatment options catering to the unique needs of patients.
Surgical interventions, including myomectomy and hysterectomy, offer definitive
solutions, while non-invasive procedures like uterine artery embolization (UAE)
and focused ultrasound provide alternatives with reduced recovery times and
minimal invasiveness.
Pharmaceutical Advancements: Pharmaceutical
innovations are contributing significantly to the uterine fibroid market, with
medications aimed at managing symptoms, controlling fibroid size, and
preserving fertility. Ongoing research and development activities focus on
enhancing the efficacy and safety profile of these pharmaceutical
interventions.
Patient-Centric Approach: As awareness about
fibroid disease grows, there is a notable shift toward a patient-centric approach
in the market. Education, support networks, and advocacy efforts are gaining
prominence, empowering individuals to make informed decisions about their
health.
Major Key Players:
Some of the uterine
fibroid companies are GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd,
Pfizer Inc, Novartis AG, Bristol-Myers Squibb Company, Sanofi, Teva
Pharmaceutical Industries Ltd., Amgen Inc, Medtronic, Endo International plc,
Mylan N.V, Sun Pharmaceutical Industries Ltd, Hologic, Inc, Smith & Nephew,
and Merck & Co., Inc.
Market Segmentation
The uterine fibroid market has been segmented into type,
diagnosis, and treatment. Based on the segment which is type, the market is
categorized on the basis of intramural fibroids, submucosal fibroids,
subserosal fibroids, and others. The global market for uterine fibroid is
further segmented based on diagnosis into computed tomography (CT), medical resonance
imaging (MRI) scanners, ultrasounds, and others. Furthermore, the market, on
the basis of treatment is segmented into endometrial ablation, hysterectomy,
magnetic resonance guided focused ultrasound, myolysis, myomectomy, and uterine
fibroid embolization.
The U.S. Uterine Fibroid Market report offers comprehensive
study of this market segments including type, diagnosis, and treatment. The
analysts have also studied the uterine fibroid market's spread across the
regional markets across many of the uterine fibroid market’s segments at
country levels. The type, diagnosis, and treatment segments spread across the
uterine fibroid market along with the subsegments are studied. The global
market for uterine fibroid is spread across various product and service based
segments. The U.S. Uterine Fibroid Market research report highlights these key
segments and offers forecasts based on primary and secondary data. The global
uterine fibroid market research report presents key company profiles of
organizations active across the U.S. Uterine Fibroid Market.
Recent Developements
June 2022: ObsEva SA, a biopharmaceutical company developing
and commercializing novel therapies for women's health, announced in June 2022
that the European Commission (EC) has granted marketing authorization for
Yselty® (linzagolix), an oral GnRH antagonist, for the management of moderate
to severe symptoms of uterine fibroids (UF) in adult women (over 18 years of
age) of reproductive age. Yselty® is the only FDA-approved oral GnRH antagonist
that offers women with UF flexible dosing alternatives with and without
supplemental hormonal therapy.
June 2022: The U.S. Food and Drug Administration (FDA) has
accepted for review a supplemental New Drug Application (sNDA) for MYFEMBREE
(relugolix 40 mg, estradiol 1 mg, and norethydrone acetate 0.5 mg) submitted by
Myovant Sciences and Pfizer Inc. in June 2022. The sNDA proposes modifications
to the United States Prescribing Information (USPI) for MYFEMBREE based on
safety and efficacy data from the Phase 3 LIBERTY randomized
Regional Overview
Higher risks associated with morcellators may hinder the
uterine fibroid market growth. The U.S. Uterine Fibroid Market research report
suggests that companies in the uterine fibroid market could be supported by
improving education and awareness levels as well as patients opting for
minimally or non-invasive uterine fibroid procedures during the forecast
period. The market for uterine fibroid is set to register growth at a high CAGR
owing to these key factors. The uterine fibroid market is spread across North
America, Europe, Asia-Pacific, and other parts of the world. As per uterine
fibroid market analysts, the uterine fibroid market is set to witness
tremendous growth across type, diagnosis, and treatment segments. The global
uterine fibroid market’s North American region covers uterine fibroid markets
across the United States, Mexico, Canada, and others. Businesses present in
this market are also profiled and their strategies have been presented in
detail in the uterine fibroid market research report.
The U.S. Uterine Fibroid Market across the European region
covers Italy, France, Germany, and the United Kingdom. Furthermore, the U.S.
Uterine Fibroid Market research report provides details about the APAC region covering
uterine fibroid markets from China, India, Australia, Japan, and others. The
uterine fibroid market is also active across several other parts of the world.
The uterine fibroid market report covers all these key regions including the
Middle East, Africa, Brazil, and others active in this market.
Browse Related Reports:
Pharmaceutical Excipients Market
For More Information, Please Visit @ Market
Research Future
Comments
Post a Comment